FDA approves Akorn’s generic Voltaren gel
Specialty generic company Akorn has received the Food and Drug Administration's clearance for its generic Voltaren gel (diclofenac sodium topical gel 1%).
Diclofenac sodium topical gel is indicated for the relief of pain of osteoarthritis of joints amenable to topical treatment, including knees and hands.
The product had a market value of approximately $357 million for the 12 months ended September 2018, according to IQVIA data.
Diclofenac sodium topical gel is indicated for the relief of pain of osteoarthritis of joints amenable to topical treatment, including knees and hands.
The product had a market value of approximately $357 million for the 12 months ended September 2018, according to IQVIA data.